Sector News

Valeant said to step up talks on potential $800M deal for Egypt’s Amoun

June 18, 2015
Life sciences
Last month, reports said Valeant was eyeing up one of Egypt’s largest drugmakers. Now, word has it, those talks have progressed, and the Canadian pharma could be ready to pull the trigger in the coming weeks.
 
The serial buyer is in advanced negotiations to buy Amoun Pharmaceutical, Bloomberg reports, though no final decision has been made–meaning any deal could still fall apart. A sale could value the company between $700 million and $800 million, the news service’s sources said in May.
 
If Valeant were to grab Amoun, it would mark its third buyout of the year. After losing out on a months-long hostile takeover try for Allergan last November, the avid dealmaker has already snapped up North Carolina’s Salix–beating out rival bidder Endo–and the assets from bankrupt Seattle biotech Dendreon in the first half of 2015.
 
But unlike those transactions–which helped the company bulk up in GI and oncology, respectively–an Amoun tie-up would strengthen Valeant in fast-growing emerging markets. Beefing up in developing nations was one perk of the proposed Allergan merger, and a goal Pearson has already worked toward with deals like 2012’s for Mexican branded-generics company Atlantis Pharma.
 
It’s all part of Valeant’s strategy to expand through M&A in high-growth spaces–both geographic and therapeutic. Before the Salix and Dendreon deals, Valeant’s moves–like the Allergan play, and its 2013 pickup of Bausch + Lomb–were centered on skincare and eye care, two other hot fields Pearson had tabbed for expansion.
 
By Carly Helfand
 

Related News

April 10, 2021

Genentech aims high with new diversity goals, including doubling hires and spending $1B with diverse suppliers

Life sciences

Quita Highsmith, Genentech’s chief diversity officer, is helping the pharma double down on diversity and inclusion goals with a new 2025 plan. 

April 10, 2021

Merck CEO Frazier joins army of Black execs speaking out on restrictive voting-rights laws

Life sciences

Merck CEO Kenneth Frazier teamed up with former American Express executive Kenneth Chenault to protest a voting-rights law passed recently in Georgia.

April 10, 2021

Zimmer Biomet bundles robotic surgery, apps and digital health programs into one orthopedics package

Life sciences

By bringing together big data and robotic procedures, the ultimate goal of the connected suite is to take some of the guesswork out of orthopedic medicine. 

Send this to a friend